COL7A1 and Dystrophic epidermolysis bullosa: In this topical in vivo gene therapy for dystrophic EB (DEB), a non-replicating herpes simplex virus (HSV) is used to deliver two copies of COL7A1 cDNA into skin cells persisting in wounds of DEB patients.